Pattern Pharma Inc.

Profile

Pattern’s patented PPI-100 activates innate immunity against cancers and infectious diseases. Pattern intends commencing a clinical study in Q1 2026 in perioperative immunotherapy to address the ~40% relapse rate 5 years after cancer surgery. PPI-100 is a GMP version of an earlier product approved in ex-US jurisdictions for use against infectious diseases, where it proved safe & efficacious during widespread use. Pattern collaborates with Massachusetts General Hospital, MD Anderson, University of Toronto and McGill.

Pattern Pharma Inc.
patternpharma.com

Contact

Event details

Date: November 9 - 11, 2026

Event contact

Patricia Cosgrove
Senior International Market Consultant
U.S.A. & Europe

Participants

24 participants

  • 20/20 OptimEyes Technologies

    20/20 OptimEyes Technologies is developing OPT-101, a sustained-release glaucoma eye drop designed to reduce dosing

  • Acanthus Pharma Services Inc.

    APS Pharma™ is a Canadian innovation-focused specialty chemistry

  • AlloWide Health

    AlloWide Health is an Ontario-based biotechnology company developing innovative solutions to improve the preparatio

  • Altis Labs

    Altis Labs is the AI endpoint company accelerating clinical trials.

  • BioBackers

    Lumerate’s investor intelligence brand, tracks global life science deal flow to reveal behavioral signals that connect you with the

  • BioScript Solutions

    BioScript Solutions is a Canadian healthcare company committed to simplifying access to specialty care.

  • Bough Bioscience

    Bough Bio is a pre-clinical stage company focused on decoding the molecular biology of senescent cells to unlock ne

  • Dalriada

    Dalriada is a Canadian small molecule discovery company focusing on unlocking challenging and undruggable targets l

  • Intrepid Labs

    Drug formulation has the power to transform promising compounds into life-saving therapies, yet this step is often an afterthought d

  • JN Nova Pharma

    JN Nova Pharma is a Canadian biotechnology company developing a proprietary platform technology to add

  • Kanata Bio

    Over 30% of organ transplant patients have complications due to CMV.

  • Medicenna Therapeutics

    Medicenna Therapeutics is a clinical-stage immunotherapy company engineering next-generation cytokine therapies for

  • Pattern Pharma Inc.

    Pattern’s patented PPI-100 activates innate immunity against cancers an

  • PlantForm Corporation

    PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of specialty a

  • ProteinQure Inc.

    ProteinQure has built the best computational platform for designing peptides for extra-cellular targets.

  • Q&C Services

    Q&C Services is Canada’s largest independent full-service consultant and importer for pharmaceutical, natural h

  • QurCan Therapeutics

    QurCan Therapeutics is advancing the next wave of genetic medicines for CNS

  • Rhythm Biotherapeutics Inc.

    Rhythm Biotherapeutics develops first-in-class, heart-derived exosome therapeutics to prevent atrial fibrillation.

  • Singularity Pharma

    Singularity Pharma is a drug discovery business developing novel therapeutics for

  • Specific Biologics

    Specific Biologics is developing Dualase®, an industry-leading genome editing platform with best-in-class accurate

  • TheraVac Biologics

    TheraVac Biologics is a late-stage preclinical company developing innovative immunotherapies for neurodegenerative

  • Transpharmation

    Transpharmation is a contract research organisation led by scientists.

  • Virano Therapeutics

    Virano is a genetic immunomodulation company, developing next-generation combination products which reprogram the i

  • YYZ Pharmatech Inc.

    YYZ Pharmatech Inc. (YYZ) is a deep tech company endeavoring to profoundly progress new medicine for p